How EYP-1901 Addresses IL-6 Drivers in Wet AMD and DME

Ehsan Rahimy, MD, and Sumit Sharma, MD, examine the unmet needs in wet AMD and DME, from insufficient disease control to injection burden. They explore the emerging role of IL-6 as a driver of both conditions review, review data to support the role that IL-6 plays in both wet AMD and DME pathogenesis.  and discuss EYP-1901 (EyePoint, Inc.), a sustained-release TKI in development for wet AMD and DME.. Phase 2  clinical data from the VERONA and DAVIO 2 trials are reviewed, including visual acuity and anatomic outcomes, and the potential for reduced treatment burden.